Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Seeks Injunction Against Aria

NEW YORK (GenomeWeb News) – Sequenom said after the close of the market on Wednesday that it has filed a motion for a preliminary injunction against Aria Diagnostics.

Sequenom is seeking to stop Aria from making, using, selling, or offering for sale, importing, or exporting tests for detecting fetal chromosomal aneuploidy that Sequenom claims infringes on a patent it holds until pending litigation is resolved.

Sequenom filed a lawsuit against Aria in January in US District Court for the Southern District of California alleging Aria infringes on US Patent No. 6,258,540. In a statement Wednesday, Sequenom mentions Aria's Harmony Prenatal Test as an infringing test.

Sequenom launched its MaterniT21 test for the detection of a genetic chromosomal anomaly called Trisomy 21 in the fall.

In December Aria filed a lawsuit against Sequenom claiming it is overly aggressive in enforcing a broad patent related to the use of circulating cell-free DNA in maternal plasma to diagnosed fetal aneuploidies.

Sequenom and Natera also have sued each other over patent-related issues, and in an analyst note today, David Ferreiro of Oppenheimer said it would not be a surprise if Sequenom sought an injunction against that firm.

The Scan

Call for a Different Tack

Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News.

Wastewater Warning

The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge.

Can't Get in the Program

Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports.

Science Paper on Spatial-Controlled Genome Editing

In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.